Filing Flows › Comparisons › VXRT vs RGNX
Vaxart vs Regenxbio: VXRT and RGNX compared
Vaxart is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $9.2M for Regenxbio (Q3 2026). Regenxbio is growing faster (-69% against -85% a year earlier). Vaxart is more profitable, with an operating margin of -162.7% against -387.8%.
Where the money goes: VXRT and RGNX
Vaxart (VXRT) · Q3 2026
Vaxart, Q3 2026: revenue $10.6M (-85% year over year), operating margin -162.7%, net loss $17.7M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
Regenxbio (RGNX) · Q3 2026
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
| Vaxart (VXRT) | Regenxbio (RGNX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.6M | $9.2M |
| Revenue growth, Y/Y | -85% | -69% |
| Operating margin | -162.7% | -387.8% |
| Net earnings | −$17.7M | −$40.7M |
| Net margin | -166.6% | -444.6% |
| Operating cash flow | $1.4M | $38.6M |
| Free cash flow | $1.1M | $38.4M |
Where the revenue comes from
Vaxart
- Government Contract: $7.5M (71%)
- Collaboration Revenue: $2.9M (28%)
- Non Cash Royalty Revenue: $154K (1%)
Regenxbio
- License and Service: $5.2M (57%)
- Service: $3.9M (43%)
Questions
Which is bigger, Vaxart or Regenxbio?
Vaxart is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $9.2M for Regenxbio (Q3 2026).
Is Vaxart or Regenxbio growing faster?
Regenxbio is growing faster (-69% against -85% a year earlier).
Which is more profitable, Vaxart or Regenxbio?
Vaxart is more profitable, with an operating margin of -162.7% against -387.8%.
More: Vaxart earnings · how Vaxart makes money · Regenxbio earnings · how Regenxbio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.